Final answer:
Addyi is part of a REMS program due to the possibility of extreme hypotension and syncope. It is used to treat hypoactive sexual desire disorder in premenopausal women.
Step-by-step explanation:
Part a. Addyi is part of a REMS program due to the possibility of extreme hypotension and syncope. REMS stands for Risk Evaluation and Mitigation Strategy, which is a program implemented by the US Food and Drug Administration (FDA) to manage known or potential risks associated with certain medications.
Addyi (generic name: flibanserin) is a medication used to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. It carries a black box warning for risk of severe hypotension and syncope, which are potentially dangerous conditions involving low blood pressure and fainting.